Skip to content
PeptidesEncyclopedia
Informational, not medical advice

This is an approved / prescription medicine. Do not use without a prescription and medical supervision.

EMA-approvedaka Vantas, Supprelin LA

Histrelin — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Histrelin (also known as Vantas) is a peptide catalogued under Sexual Health (GnRH agonist). It is described as: GnRH receptor agonist. Documented context: Prostate cancer; precocious puberty. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Histrelin?

Histrelin is a potent GnRH-agonist analog delivered as a subcutaneous implant.

Supprelin LA is FDA-approved for central precocious puberty in children, while Vantas was approved for advanced prostate cancer (Vantas has since been discontinued).

The implant provides roughly 12 months of continuous drug release, and its efficacy is supported by human multicenter trials in both indications.

How does Histrelin work?

Histrelin initially stimulates pituitary GnRH receptors, producing a transient flare in LH, FSH and sex steroids.

Continuous release from the implant then desensitizes and downregulates the pituitary, giving sustained suppression of gonadotropins and sex hormones over the life of the implant.

What does the research say about Histrelin?

  • The histrelin subdermal implant effectively suppresses the pituitary-gonadal axis in children with central precocious puberty. [1]
  • In advanced prostate cancer, the histrelin implant achieves and maintains castrate testosterone levels over 12 months. [2]
  • Suppression is reversible: puberty resumes after the histrelin implant is removed. [4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

  • [1] Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial — Eugster EA et al., Journal of Clinical Endocrinology and Metabolism 2007. (Multicenter clinical trial)
  • [2] Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer — Schlegel PN et al., Journal of Urology 2006. (Clinical trial)
  • [3] Time to menarche and final height after histrelin implant treatment for central precocious puberty — Gillis D et al., Journal of Pediatrics 2013. (Longitudinal outcome study)
  • [4] Resumption of puberty in girls and boys following removal of the histrelin implant — Fisher MM et al., Journal of Pediatrics 2014. (Outcome study)
  • [5] Histrelin: in advanced prostate cancer — Deeks ED et al., Drugs 2010. (Drug review)
  • [6] The histrelin implant: a novel treatment for central precocious puberty — Hirsch HJ et al., Pediatrics 2005. (Clinical study)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Histrelin is administered only as a physician-inserted subcutaneous implant that is replaced approximately every 12 months, not as a self-administered dose.

All insertion, monitoring and replacement decisions are made by the treating specialist for the approved indication.

Side effects & safety profile

As a GnRH agonist, histrelin causes an initial testosterone/estrogen flare before suppression, relevant to symptom flare in prostate cancer.

Adults experience hot flushes and other vasomotor symptoms, and implant-site reactions can occur.

Prolonged sex-steroid suppression reduces bone mineral density, a particular monitoring concern with long-term use.

Stacking & combinations

It is used as a standalone endocrine therapy; any adjuncts (for example anti-androgen cover at initiation in prostate cancer) are added strictly under medical supervision.

Finding Histrelin vendors

Finding Histrelin vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Sign in to review

Frequently asked questions

Supprelin LA is FDA-approved for central precocious puberty; Vantas was approved for advanced prostate cancer but has been discontinued.

References

  1. [1] Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial — Eugster EA et al., Journal of Clinical Endocrinology and Metabolism 2007. PMID: 17327379. View sourceStudy: Multicenter clinical trialThe histrelin implant suppressed gonadotropins and sex steroids in central precocious puberty with a favorable safety profile.
  2. [2] Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer — Schlegel PN et al., Journal of Urology 2006. PMID: 16515997. View sourceStudy: Clinical trialThe histrelin implant achieved and maintained castrate testosterone levels over 12 months in advanced prostate cancer.
  3. [3] Time to menarche and final height after histrelin implant treatment for central precocious puberty — Gillis D et al., Journal of Pediatrics 2013. PMID: 23485026. View sourceStudy: Longitudinal outcome studyReports menarche timing and adult-height outcomes following histrelin implant therapy for precocious puberty.
  4. [4] Resumption of puberty in girls and boys following removal of the histrelin implant — Fisher MM et al., Journal of Pediatrics 2014. PMID: 24433825. View sourceStudy: Outcome studyPubertal development resumed after implant removal, confirming reversibility of suppression.
  5. [5] Histrelin: in advanced prostate cancer — Deeks ED et al., Drugs 2010. PMID: 20329807. View sourceStudy: Drug reviewReviews the histrelin implant's efficacy and safety for androgen suppression in advanced prostate cancer.
  6. [6] The histrelin implant: a novel treatment for central precocious puberty — Hirsch HJ et al., Pediatrics 2005. PMID: 16322137. View sourceStudy: Clinical studyThe subcutaneous histrelin implant provided effective 12-month suppression in central precocious puberty.
This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.